NCT01024387View on ClinicalTrials.gov

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2017

Conditions
Neuroendocrine TumorCarcinoid TumorPancreatic Neuroendocrine Tumor
Interventions
DRUG

AMG 479

Trial Locations (3)

33612

H. Lee Moffitt Cancer Center, Tampa

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

collaborator

Amgen

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT01024387 - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter